Effect of early prophylactic high-dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 315, Issue 19, 2016, Pages 2079-2085

  Natalucci, Giancarlo ^a,b   Latal, Beatrice ^b   Koller, Brigitte ^a   Rüegger, Christoph ^a   Sick, Beate ^c   Held, Leonhard ^c   Bucher, Hans Ulrich ^a   Fauchère, Jean Claude ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN; NEUROPROTECTIVE AGENT; RECOMBINANT PROTEIN;

ARTICLE; BAYLEY SCALES OF INFANT DEVELOPMENT; BODY HEIGHT; BODY WEIGHT; CEREBRAL PALSY; CHILD; COGNITIVE DEVELOPMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HEAD CIRCUMFERENCE; HEARING IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEVELOPMENT ASSESSMENT; MENTAL DEVELOPMENTAL INDEX; MULTICENTER STUDY; NEUROPROTECTION; NEWBORN; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SWITZERLAND; VISUAL IMPAIRMENT; CHILD DEVELOPMENT; CLINICAL TRIAL; DEVELOPMENTAL DISABILITIES; DRUG ADMINISTRATION; INTENTION TO TREAT ANALYSIS; NEURODEVELOPMENTAL DISORDERS; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

CHILD DEVELOPMENT; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTENTION TO TREAT ANALYSIS; MALE; NEURODEVELOPMENTAL DISORDERS; NEUROPROTECTIVE AGENTS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84969194630     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.5504     Document Type: Article

References (39)

1. Volpe JJ. The encephalopathy of prematurity-brain injury and impaired brain development inextricably intertwined. Semin Pediatr Neurol. 2009;16(4):167-178.
2. Robertson NJ, Tan S, Groenendaal F, et al. Which neuroprotective agents are ready for bench to bedside translation in the newborn infant? J Pediatr. 2012;160(4):544-552.
3. Koulnis M, Porpiglia E, Hidalgo D, Socolovsky M. Erythropoiesis: from molecular pathways to system properties. Adv Exp Med Biol. 2014;844:37-58.
4. Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M. Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol. 2011;82(10):1291-1303.
5. Rangarajan V, Juul SE. Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection. Pediatr Neurol. 2014;51(4):481-488.
6. Juul S. Neuroprotective role of erythropoietin in neonates. J Matern Fetal Neonatal Med. 2012;25 (suppl 4):105-107.
7. Kumral A, Tüzün F, Oner MG, Genç S, Duman N, Ozkan H. Erythropoietin in neonatal brain protection: the past, the present and the future. Brain Dev. 2011;33(8):632-643.
8. Wu YW, Gonzalez FF. Erythropoietin: a novel therapy for hypoxic-ischaemic encephalopathy? Dev Med Child Neurol. 2015;57(suppl 3):34-39.
9. Benders MJ, van der Aa NE, Roks M, et al. Feasibility and safety of erythropoietin for neuroprotection after perinatal arterial ischemic stroke. J Pediatr.2014;164(3):481-486.
10. Neubauer AP, Voss W, Wachtendorf M, Jungmann T. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann Neurol. 2010;67(5):657-666.
11. Ohls RK, Kamath-Rayne BD, Christensen RD, et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics. 2014;133(6):1023-1030.
12. Fauchère JC, Koller BM, Tschopp A, Dame C, Ruegger C, Bucher HU; Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high-dose recombinant erythropoietin for neuroprotection in very preterm infants. J Pediatr. 2015;167(1):52-57.
13. Suk KK, Dunbar JA, Liu A, et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS. 2008;12(3):233-238.
14. Leuchter RH, Gui L, Poncet A, et al. Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. JAMA.2014; 312(8):817-824.
15. O'Gorman RL, Bucher HU, Held U, Koller BM, Hüppi PS, Hagmann CF; Swiss EPO Neuroprotection Trial Group. Tract-based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain. 2015;138(pt 2):388-397.
16. Toet MC, Hellström-Westas L, Groenendaal F, Eken P, de Vries LS. Amplitude integrated EEG 3 and 6 hours after birth in full term neonates with hypoxic-ischaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed. 1999;81(1):F19-F23.
17. Fauchère JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008;122(2):375-382.
18. Voigt M, Fusch C, Olbertz D, et al. Analysis of the Neonatal Collective in the Federal Republic of Germany 12th Report: presentation of detailed percentiles for the body measurements of newborns. Geburtshilfe Frauenheilkd. 2006;66: 956-970.
19. Volpe JJ. Intracranial hemorrhage: germinal matrix hemorrhage. In: Volpe JJ, ed. Neurology of the Newborn. Philadelphia, PA: Saunders Elsevier; 2008:517-288.
20. de Vries LS, Eken P, Dubowitz LM. The spectrum of leukomalacia using cranial ultrasound.Behav Brain Res. 1992;49(1):1-6.
21. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7): 1723-1729.
22. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123(7):991-999.
23. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis: therapeutic decisions based upon clinical staging. Ann Surg. 1978;187(1):1-7.
24. Schlapbach LJ, Aebischer M, Adams M, et al; Swiss Neonatal Network and Follow-up Group. Impact of sepsis on neurodevelopmental outcome in a Swiss national cohort of extremely premature infants. Pediatrics. 2011;128(2):e348-e357.
25. Largo RH, Pfister D, Molinari L, Kundu S, Lipp A, Duc G. Significance of prenatal, perinatal and postnatal factors in the development of AGA preterm infants at five to seven years. Dev Med Child Neurol. 1989;31(4):440-456.
26. Bayley N. Bayley Scales of Infant Development.
27. 2nd ed. San Antonio, TX: Psychological Corporation; 1993.
28. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol.1997; 39(4):214-223.
29. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. http: //www.R-project.org/. Accessed April 18, 2016.
30. Rüegger CM, Hagmann CF, Bührer C, Held L, Bucher HU, Wellmann S; EpoRepair Investigators. Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants (EpoRepair). Neonatology. 2015;108(3):198-204.
31. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics. 2006;118(3):e635-e640.
32. Brown MS, Eichorst D, Lala-Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics. 2009;124(4):e681-e687.
33. Ohls RK, Ehrenkranz RA, Das A, et al; National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics. 2004;114(5):1287-1291.
34. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics. 2008;122(2):383-391.
35. Marlow N. Is survival and neurodevelopmental impairment at 2 years of age the gold standard outcome for neonatal studies? Arch Dis Child Fetal Neonatal Ed. 2015;100(1):F82-F84.
36. Hack M, Taylor HG, Drotar D, et al. Poor predictive validity of the Bayley Scales of Infant Development for cognitive function of extremely low birth weight children at school age. Pediatrics. 2005;116(2):333-341.
37. Luttikhuizen dos Santos ES, de Kieviet JF, Königs M, van Elburg RM, Oosterlaan J. Predictive value of the Bayley Scales of Infant Development on development of very preterm/very low birth weight children: a meta-analysis. Early Hum Dev. 2013;89 (7):487-496.
38. Marlow N, Wolke D, Bracewell MA, Samara M; EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med.2005;352 (1):9-19.
39. Schlapbach LJ, Adams M, Proietti E, et al; Swiss Neonatal Network & Follow-up Group. Outcome at two years of age in a Swiss national cohort of extremely preterm infants born between 2000 and 2008. BMC Pediatr. 2012;12:198.